All In Biotech

Drug Trial Radar · NCT01197378

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis

Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

60

Actual

Start

Aug 27, 2010

Primary completion

Jun 26, 2017

Study completion Jun 26, 2017

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Sep 9, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cystinosis is an inherited disease that if untreated, results in kidney failure as early as the first decade of life. The current marketed therapy is Cystagon® (cysteamine bitartrate immediate release) which must be taken every six hours for the rest of the patient's life to prevent complications of cystinosis. Cysteamine bitartrate delayed-release capsules (RP103) is a formulation of cysteamine bitartrate that is being studied to see if it can be given less frequently, once every 12 hours, and have similar results to four times a day Cystagon®.

Conditions

  • Cystinosis

Interventions

  • Cysteamine Bitartrate Delayed-release CapsulesDrug

    Participants who entered the trial from the RP103-03 study continued treatment with cysteamine bitartrate every 12 hours at the last dose level prescribed during their participation in that study. Participants not entering the trial from Study RP103-03 were started on twice a day administration of cysteamine bitartrate at a total daily RP103 dose of 70% of their pre-study total daily stable Cystagon® dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse EventsTime frame: From first dose of study drug to 7 days after the last dose; median duration of treatment was 1461 days.

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • California Pacific Medical Center (CPMC) Research Institute

    San Francisco, California

  • Stanford University Medical School

    Stanford, California

  • Emory Children's Center

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Texas Children's Hospital/Baylor University

    Houston, Texas

  • Hospices Civils de Lyon

    Lyon, France

  • Hôpital Arnaud Villeneuve - CHU Montpellier

    Montpellier, France

  • Hopital Necker

    Paris, France

  • Robert Debre Hospital

    Paris, France

  • Radboud University Nijmegen Medical Center

    Nijmegen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.